Education
About Us
Working with TipRanks
Follow Us
Larimar Therapeutics, Inc. (LRMR)
NASDAQ:LRMR
LRMR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.61 - $9.50
Previous CloseN/A
Volume147.46K
Average Volume (3M)1.45M
Market Cap
$436.51M
Enterprise Value$51.13M
Total Cash (Recent Filing)$138.52M
Total Debt (Recent Filing)$4.61M
Price to Earnings (P/E)―
Beta2.20
Next Earnings
Nov 18, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding85,590,390
10 Day Avg. Volume1,625,812
30 Day Avg. Volume1,454,281
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.12
Enterprise Value/Revenue106.08
Enterprise Value/Gross Profit-6.39K
Enterprise Value/Ebitda-0.47
Forecast
1Y Price Target
$21.00Price Target Upside332.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Analyst OutlookAnalyst reiterates Outperform and $25 PT.
Market CompetitionPTCT’s CRL removes a near-term commercial competitor, potentially benefiting Larimar's Ph3 trial enrollment.
Regulatory ApprovalThe FDA has communicated that frataxin concentrations in skin could serve as the basis for accelerated approval, supporting Larimar's pathway for approval.
Bears Say
Market SaturationThe market for Skyclarys has become somewhat saturated early on, or there might be more concerning drivers hindering US growth.
Treatment Discontinuation8.8% of initiators have discontinued treatment largely due to lack of perceived benefit, intolerability, and/or access.
Larimar Therapeutics News
LRMR FAQ
What was Larimar Therapeutics, Inc.’s price range in the past 12 months?
Larimar Therapeutics, Inc. lowest stock price was $1.61 and its highest was $9.50 in the past 12 months.
What is Larimar Therapeutics, Inc.’s market cap?
Larimar Therapeutics, Inc.’s market cap is $436.51M.
When is Larimar Therapeutics, Inc.’s upcoming earnings report date?
Larimar Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 53 days.
How were Larimar Therapeutics, Inc.’s earnings last quarter?
Larimar Therapeutics, Inc. released its earnings results on Aug 14, 2025. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.48 by $0.07.
Is Larimar Therapeutics, Inc. overvalued?
According to Wall Street analysts Larimar Therapeutics, Inc.’s price is currently Undervalued.
Does Larimar Therapeutics, Inc. pay dividends?
Larimar Therapeutics, Inc. does not currently pay dividends.
What is Larimar Therapeutics, Inc.’s EPS estimate?
Larimar Therapeutics, Inc.’s EPS estimate is -0.41.
How many shares outstanding does Larimar Therapeutics, Inc. have?
Larimar Therapeutics, Inc. has 85,590,390 shares outstanding.
What happened to Larimar Therapeutics, Inc.’s price movement after its last earnings report?
Larimar Therapeutics, Inc. reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.48. Following the earnings report the stock price went up 14.516%.
Which hedge fund is a major shareholder of Larimar Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LRMR
Larimar Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.00 (332.10% Upside)
$21.00 (332.10% Upside)
Blogger Sentiment
Bullish
LRMR Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 249.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 17.0%
Last 30 Days ▲ 17.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.43%
12-Months-Change
Fundamentals
Return on Equity
-60.25%
Trailing 12-Months
Asset Growth
-36.76%
Trailing 12-Months
Company Description
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
LRMR Stock 12 Month Forecast
Average Price Target
$21.00
▲(332.10% Upside)
Technical Analysis
Nektar Therapeutics
―
Tonix Pharma
―
Aldeyra Therapeutics
―
Kodiak Sciences
―
RAPT Therapeutics
―
Ownership Overview
35.39% Insiders
5.32% Mutual Funds
0.43% Other Institutional Investors
52.44% Public Companies and Individual Investors